Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

Figure 5

siRNA-Wee1 treatment confirms that the selected genes are the bona-fide Wee1 inhibition gene signature. WiDr colorectal cancer cells were treated with 30 nM of gemcitabine and siRNA for Wee1. After 48 hr siRNA treatment, mRNA from each was applied to quantitative RT-PCR analysis for the Wee1 gene signature. Gem: gemcitabine. Data represent mean ± SD. **, P < 0.01, compared with gemcitabine treated sample.

Back to article page

Molecular Cancer

ISSN: 1476-4598